Summary
We are delighted to share that the ICM - Institut du Cancer de Montpellier was authorized by the French Data Protection Authority (CNIL) to conduct APAD-ECO study.
The CNIL granted authorization to conduct a medico-economic study on the effects of physical activity in women treated for breast cancer on April, 19th. This groundbreaking study involves combining data from two clinical trials with that of the Caisse nationale de l’Assurance Maladie, covering the period from 2009 to 2022.
The study aims to assess the long-term impacts of physical activity in patients who have undergone treatment for breast cancer.
We are proud to have contributed to this project by providing the ICM - Institut du Cancer de Montpellier with a compliant Data Protection Impact Assessment (DPIA), a crucial step in obtaining CNIL approval.
FAQs
Our frequently questions
Find out how iliomad can help your company.
Only visible in production
Medical trials and AI: navigating the GDPR, EHDS and EU AI Act overlap
Legal uncertainty surrounds AI use in medical trials. Learn how GDPR, the EHDS and the EU AI Act interact and what sponsors must do to stay compliant.
AI passports and EHDS: what the CHAIN network means for health AI governance
The EU CHAIN network introduces AI Passports and federated health data models. Learn what this means for GDPR compliance, high-risk AI obligations and clinical sites.
Healthcare Data Breaches, AI Transparency and Clinical Research Standards: Weekly Digest
This week: Danish CPR breach, IQVIA Garante fine, OpenAI EU watermarking, Epic MyChart flaws, NIH funding decline and cancer trial QoL standards.
